SHARE

Roche expands testing of new antibiotic targeting resistant superbugs

The Swiss pharmaceutical company is planning to move the new antibiotic into late stage clinical trials after studies showed it had the potential to tackle a common superbug. It would be the first new class of antibiotic capable of killing acinetobacter.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.